Oncocyte to Announce Second Quarter 2022 Financial Results
Oncocyte Corporation (Nasdaq: OCX) announced the release date for its second quarter 2022 financial results, scheduled for August 10, 2022. The company will host a conference call and webcast at 1:30 PM PT / 4:30 PM ET to discuss these results along with recent highlights. Interested participants can join the call via phone or through the company's website. Oncocyte is focused on improving patient outcomes through precision diagnostics, offering tests like DetermaRx™ and DetermaIO™ that support cancer diagnosis and treatment decisions.
- Oncocyte's upcoming financial results announcement may provide insights into business performance.
- The company's ongoing development of diagnostic tests demonstrates a focus on innovation in cancer care.
- None.
IRVINE, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, announced today that it will release its second quarter 2022 financial results on Wednesday, August 10, 2022. In conjunction with the release, Oncocyte will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live call via telephone by dialing (877) 407-9716 for domestic callers or (201) 493-6779 for international callers, using conference ID: 13731553. The live webinar of the call may be accessed by visiting the “Events & Presentation” section of the Company’s website at https://investors.oncocyte.com. A replay of the webinar will be available on the Company’s website shortly after the conclusion of the call.
About Oncocyte
Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.
Through its proprietary tests and pharmaceutical services business, the Company aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The Company’s pipeline of tests in development also includes DetermaTx™, which will assess mutational status of a tumor, DetermaCNI™, a blood-based monitoring test, DetermaMx™, a long-term recurrence monitoring test, and VitaGraft™, a blood-based solid organ transplantation monitoring test. In addition, Oncocyte’s pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.
DetermaRx™, DetermaIO™, DetermaTx™, DetermaCNI™, DetermaMx™ and VitaGraft™ are trademarks of Oncocyte Corporation.
Investor Contact
Caroline Corner
ICR Westwicke
(415) 202-5678
caroline.corner@westwicke.com
Media Contact
Megan Kernan
ICR Westwicke Healthcare PR
Tel: 646.677.1870
Megan.kernan@westwicke.com
FAQ
When will Oncocyte Corporation release its second quarter 2022 financial results?
What time is Oncocyte's conference call for its Q2 2022 financial results?
How can I access Oncocyte's Q2 2022 financial results conference call?
What are Oncocyte's primary products mentioned in the press release?
